 Home > Active Ingredient News > Drugs Articles > Kelun Botai: The third domestically produced PD-L1 monoclonal antibody reported for listing

Kelun Botai: The third domestically produced PD-L1 monoclonal antibody reported for listing

 Last Update: 2021-12-06
 Source: Internet
 Author: User

Tags

plastics 1 7

folic acid injection

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

introduction

November 19, 2021, drug trial center hosted fourBiological Pharmaceutical Co.
, Ltd.
Class 1 biological products Tetley monoclonal antibody injection in clinical application
.

Sichuan Kelunbotai Biomedical Co.
, Ltd.
Tetlizumab Injection

(Source: CDE official website)

Tetley monoclonal antibody injection Tetley monoclonal antibody injection (codename: KL-A167) is a PD-L1 monoclonal antibody injection , is the second Corning Jerry 's Enwo Li monoclonal antibody injection , the cornerstone of Pharmaceutical After the sugarizumab injection , the third paragraph declares the domestically produced PD-L1 monoclonal antibody for the market
.

Tetley monoclonal antibody injection PD-L1 monoclonal antibody injection Corning Jerry Enwo Li monoclonal antibody injection cornerstone Pharmaceutical Shu Geli monoclonal antibody injection , paragraph 3 of the declaration listed domestic PD-L1 monoclonal antibody

(Domestic PD-1/PD-L1 monoclonal antibodies that have been marketed/declared for listing: Sorting out: Target Society)

Today, the competition of PD-1 monoclonal antibody has become fierce.
Although the commercialization of domestic PD-L1 antibody is still close to the door, the degree of competition in the future is also predictable
.

In addition to the three PD-L1 monoclonal antibodies that are being declared, there are dozens of PD-L1 antibodies still in the development stage

(PD-L1 drugs in research and development finishing: Target Society) Columbotai

Columbote

Kelun Pharmaceutical is a highly specialized and innovative pharmaceutical group.
Its subsidiaries include Sichuan Kelun Pharmaceutical Co.
, Ltd.
, Sichuan Kelun Botai Biomedical Co.
, Ltd.
, Sichuan Kelun Pharmaceutical Research Institute Co.
, Ltd.
, and Klus Pharma Inc.
USA Cologne), Cologne KAZ pharmaceutical Co.
, Ltd.
(Kazakhstan Cologne), Sichuan Kelun pharmaceutical Co.
, Ltd.
and so on more than 100 enterprises at home and abroad
.

It is reported that Kelun currently has 89 projects in the oncology field, including 54 targeted therapies, 20 immunotherapeutic drugs, 8 cytotoxic drugs and 7 tumor support therapies; 46 of which are innovative drugs, so far Eight innovative projects have been approved for INDs, including 1 NDA application submission, 1 phase III study, 1 critical phase II study, 1 phase II study, 3 phase I studies, and 1 IND pending approval
.

So far, Kelun has approved 6 anti-tumor drugs, namely Keyuxin® (gefitinib tablets), Keshulan® (zoledronic acid injection 100ml: 4mg), Keruifei®- Paclitaxel (albumin-bound type) for injection, Keshuxin® (sunitinib malate capsules), afatinib maleate tablets and Korrel® (erlotinib hydrochloride tablets)

(Product pipeline source: Klus Pharma Inc.

Reference source:

Reference source: Reference source:

[1] CDE official website

[2] Kelun official website | Kelun official website | [3] KLUS Pharma | https:// KLUS Pharma | https://

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.